IFNG and lung cancer: Additionally, Selumetinib also appears to attenuate PD-L1 expression without impeding interferon gamma (IFNγ)-induced MHC-I upregulation in nonsmall cell lung cancer cells, suggesting that it may also benefit patients receiving cancer immunotherapy [39].